OTCMKTS:CYDY - CytoDyn Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.54 +0.05 (+10.20 %)
(As of 07/18/2018 03:00 AM ET)
Previous Close$0.4950
Today's Range$0.4701 - $0.5940
52-Week Range$0.40 - $0.8360
Volume1.61 million shs
Average Volume197,138 shs
Market Capitalization$94.15 million
P/E Ratio-2.84
Dividend YieldN/A
Beta0.54
CytoDyn logoCytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. The company is based in Vancouver, Washington.

Receive CYDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:CYDY
CUSIPN/A
Phone360-980-8524

Debt

Debt-to-Equity RatioN/A
Current Ratio0.53
Quick Ratio0.53

Price-To-Earnings

Trailing P/E Ratio-2.84
Forward P/E Ratio-1.74
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.01) per share
Price / Book-54.00

Profitability

EPS (Most Recent Fiscal Year)($0.19)
Net Income$-25,760,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-654.43%

Miscellaneous

Employees146
Outstanding Shares218,090,000
Market Cap$94.15

The Truth About Cryptocurrencies

CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How were CytoDyn's earnings last quarter?

CytoDyn Inc (OTCMKTS:CYDY) issued its quarterly earnings data on Tuesday, October, 10th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.03. View CytoDyn's Earnings History.

When is CytoDyn's next earnings date?

CytoDyn is scheduled to release their next quarterly earnings announcement on Thursday, July, 19th 2018. View Earnings Estimates for CytoDyn.

What price target have analysts set for CYDY?

1 analysts have issued 1-year target prices for CytoDyn's shares. Their forecasts range from $2.00 to $2.00. On average, they expect CytoDyn's stock price to reach $2.00 in the next year. This suggests a possible upside of 270.4% from the stock's current price. View Analyst Ratings for CytoDyn.

What is the consensus analysts' recommendation for CytoDyn?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of CytoDyn's key competitors?

Who are CytoDyn's key executives?

CytoDyn's management team includes the folowing people:
  • Mr. Anthony D. Caracciolo, Exec. Chairman (Age 63)
  • Dr. Nader Z. Pourhassan, CEO, Pres & Director (Age 55)
  • Dr. Denis R. Burger, Vice Chairman & Chief Science Officer (Age 74)
  • Mr. Michael D. Mulholland, CFO, Treasurer & Corp. Sec. (Age 66)

Has CytoDyn been receiving favorable news coverage?

Media stories about CYDY stock have trended positive this week, according to Accern. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CytoDyn earned a media sentiment score of 0.35 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.03 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of CytoDyn?

Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytoDyn's stock price today?

One share of CYDY stock can currently be purchased for approximately $0.54.

How big of a company is CytoDyn?

CytoDyn has a market capitalization of $94.15 million. The biotechnology company earns $-25,760,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. CytoDyn employs 146 workers across the globe.

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected]


MarketBeat Community Rating for CytoDyn (OTCMKTS CYDY)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  166
MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe CYDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.